Orthofix Medical (OFIX) investor relations material

Leadership transition and strategic focus

• New leadership in 2024 prioritized stabilizing operations, strengthening the balance sheet, and building a focused leadership team.

• Emphasis on innovation and optimizing the commercial model across Spine, OTS, and Limb Reconstruction verticals.

• Rationalized the portfolio to define clear market segments, particularly in Limb Reconstruction.

Innovation and product launches

• Preparing for a major multi-year launch of the Virata Spinal Fixation System, targeting multiple spine market segments.

• Continued investment in the 7D enabling technology platform, with strong pull-through on hardware sales.

• TrueLok Elevate in Limb Reconstruction and other targeted innovations are driving commercial success.

Financial performance and guidance

• Q1 normalized growth was approximately 5%, in line with expectations, with no anticipated clawback from international stocking.

• CMS TEAM pilot program had a limited, one-time impact, less than initially expected.

• CMS reimbursement for bone growth stimulators decreased by about 10% for Medicare, impacting guidance and prompting cost discipline measures.

• Updated EBITDA guidance reflects a $5 million reduction at the midpoint, with ongoing cost structure reviews and operational discipline.

• Back half of the year expected to see about 4% revenue growth, adjusted for CMS changes.